Trials / Completed
CompletedNCT01683409
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2 Study to Evaluate the Safety and Renal Efficacy of Baricitinib in Patients With Diabetic Kidney Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 130 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a dose ranging study to evaluate the safety and efficacy of baricitinib in the treatment of participants with mild to moderate diabetic kidney disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Baricitinib | Administered orally |
| DRUG | Placebo | Administered orally |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2014-09-01
- Completion
- 2014-11-01
- First posted
- 2012-09-11
- Last updated
- 2019-09-30
- Results posted
- 2017-07-02
Locations
45 sites across 4 countries: United States, Japan, Mexico, Puerto Rico
Source: ClinicalTrials.gov record NCT01683409. Inclusion in this directory is not an endorsement.